These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37183242)

  • 41. Respiratory syncytial virus infection and disease in infants and young children observed from birth in Kilifi District, Kenya.
    Nokes DJ; Okiro EA; Ngama M; Ochola R; White LJ; Scott PD; English M; Cane PA; Medley GF
    Clin Infect Dis; 2008 Jan; 46(1):50-7. PubMed ID: 18171213
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus.
    Hervé PL; Dhelft V; Zuniga A; Ghasparian A; Rassek O; Yim KC; Donne N; Lambert PH; Benhamou PH; Sampson HA; Mondoulet L
    Vaccine; 2021 Jul; 39(32):4555-4563. PubMed ID: 34154864
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
    Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Maternal immunization with RSV fusion glycoprotein vaccine and substantial protection of neonatal baboons against respiratory syncytial virus pulmonary challenge.
    Welliver RC; Papin JF; Preno A; Ivanov V; Tian JH; Lu H; Guebre-Xabier M; Flyer D; Massare MJ; Glenn G; Ellingsworth L; Smith G
    Vaccine; 2020 Jan; 38(5):1258-1270. PubMed ID: 31761502
    [TBL] [Abstract][Full Text] [Related]  

  • 45. RSV awareness, risk perception, causes, and terms: Perspectives of pregnant and lactating women in Kenya to inform demand generation efforts for maternal RSV vaccines.
    Limaye RJ; Fesshaye B; Singh P; Karron RA
    Hum Vaccin Immunother; 2023 Aug; 19(2):2258580. PubMed ID: 37807864
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vaccine Induced Herd Immunity for Control of Respiratory Syncytial Virus Disease in a Low-Income Country Setting.
    Kinyanjui TM; House TA; Kiti MC; Cane PA; Nokes DJ; Medley GF
    PLoS One; 2015; 10(9):e0138018. PubMed ID: 26390032
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The disease burden of respiratory syncytial virus in older adults.
    Kenmoe S; Nair H
    Curr Opin Infect Dis; 2024 Apr; 37(2):129-136. PubMed ID: 38197402
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Passive protection against respiratory syncytial virus disease in infants: the role of maternal antibody.
    Englund JA
    Pediatr Infect Dis J; 1994 May; 13(5):449-53. PubMed ID: 8072835
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Live-attenuated Vaccines Prevent Respiratory Syncytial Virus-associated Illness in Young Children.
    Karron RA; Atwell JE; McFarland EJ; Cunningham CK; Muresan P; Perlowski C; Libous J; Spector SA; Yogev R; Aziz M; Woods S; Wanionek K; Collins PL; Buchholz UJ
    Am J Respir Crit Care Med; 2021 Mar; 203(5):594-603. PubMed ID: 32871092
    [No Abstract]   [Full Text] [Related]  

  • 50. Respiratory Syncytial Virus Consortium in Europe (RESCEU) Birth Cohort Study: Defining the Burden of Infant Respiratory Syncytial Virus Disease in Europe.
    Wildenbeest JG; Zuurbier RP; Korsten K; van Houten MA; Billard MN; Derksen-Lazet N; Snape MD; Drysdale SB; Robinson H; Pollard AJ; Heikkinen T; Cunningham S; Leach A; Martinón-Torres F; Rodríguez-Tenreiro Sánchez C; Gómez-Carballa A; Bont LJ;
    J Infect Dis; 2020 Oct; 222(Suppl 7):S606-S612. PubMed ID: 32794574
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Estimating the Economic Impact of Respiratory Syncytial Virus and Other Acute Respiratory Infections Among Infants Receiving Care at a Referral Hospital in Malawi.
    Baral R; Mambule I; Vodicka E; French N; Everett D; Pecenka C; Bar-Zeev N
    J Pediatric Infect Dis Soc; 2020 Dec; 9(6):738-745. PubMed ID: 33347578
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape.
    Mazur NI; Terstappen J; Baral R; Bardají A; Beutels P; Buchholz UJ; Cohen C; Crowe JE; Cutland CL; Eckert L; Feikin D; Fitzpatrick T; Fong Y; Graham BS; Heikkinen T; Higgins D; Hirve S; Klugman KP; Kragten-Tabatabaie L; Lemey P; Libster R; Löwensteyn Y; Mejias A; Munoz FM; Munywoki PK; Mwananyanda L; Nair H; Nunes MC; Ramilo O; Richmond P; Ruckwardt TJ; Sande C; Srikantiah P; Thacker N; Waldstein KA; Weinberger D; Wildenbeest J; Wiseman D; Zar HJ; Zambon M; Bont L
    Lancet Infect Dis; 2023 Jan; 23(1):e2-e21. PubMed ID: 35952703
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands.
    Meijboom MJ; Rozenbaum MH; Benedictus A; Luytjes W; Kneyber MC; Wilschut JC; Hak E; Postma MJ
    Vaccine; 2012 Jun; 30(31):4691-700. PubMed ID: 22561315
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Medical burden of respiratory syncytial virus and parainfluenza virus type 3 infection among US children. Implications for design of vaccine trials.
    Lee MS; Walker RE; Mendelman PM
    Hum Vaccin; 2005; 1(1):6-11. PubMed ID: 17038832
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adjustable Algorithmic Tool for Assessing the Effectiveness of Maternal Respiratory Syncytial Virus (RSV) Vaccination on Infant Mortality in Developing Countries.
    Cevigney R; Leary C; Gonik B
    Infect Dis Obstet Gynecol; 2021; 2021():5536633. PubMed ID: 34121834
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review.
    Shan J; Britton PN; King CL; Booy R
    Influenza Other Respir Viruses; 2021 Jul; 15(4):539-551. PubMed ID: 33764693
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Respiratory syncytial virus immunoglobulin and monoclonal antibodies in the prevention and treatment of respiratory syncytial virus infection.
    Welliver RC
    Semin Perinatol; 1998 Feb; 22(1):87-95. PubMed ID: 9523402
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost of childhood RSV management and cost-effectiveness of RSV interventions: a systematic review from a low- and middle-income country perspective.
    Wittenauer R; Pecenka C; Baral R
    BMC Med; 2023 Mar; 21(1):121. PubMed ID: 37004038
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 60. RSV associated hospitalizations in children in Karachi, Pakistan: Implications for vaccine prevention strategies.
    Ali A; Yousafzai MT; Waris R; Jafri F; Aziz F; Abbasi IN; Zaidi A
    J Med Virol; 2017 Jul; 89(7):1151-1157. PubMed ID: 28092107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.